Although, so far, none of the reported flavonoids have been studied in clinical settings for their TRAIL-sensitizing ability, some clinical trials have evaluated the anti-cancer effects of specific flavonoids (e.g., epigallocatechin-3-gallate, quercetin, apigenin, genistein, fisetin, and xanthohumol), showing more positive outcomes for hematopoietic and lymphoid tissues than for solid tumors [109,110,111]. The gene discussed is TNFSF10; the disease is cancer.